ATE516027T1 - Orazamid orotat zur vorbeugung von leberschäden - Google Patents

Orazamid orotat zur vorbeugung von leberschäden

Info

Publication number
ATE516027T1
ATE516027T1 AT00928256T AT00928256T ATE516027T1 AT E516027 T1 ATE516027 T1 AT E516027T1 AT 00928256 T AT00928256 T AT 00928256T AT 00928256 T AT00928256 T AT 00928256T AT E516027 T1 ATE516027 T1 AT E516027T1
Authority
AT
Austria
Prior art keywords
orotat
orazamid
liver damage
prevent liver
prevent
Prior art date
Application number
AT00928256T
Other languages
English (en)
Inventor
Rashida A Karmali
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Application granted granted Critical
Publication of ATE516027T1 publication Critical patent/ATE516027T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
AT00928256T 1999-04-20 2000-04-20 Orazamid orotat zur vorbeugung von leberschäden ATE516027T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/295,639 US6184227B1 (en) 1995-07-21 1999-04-20 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
PCT/US2000/010690 WO2000078311A1 (en) 1999-04-20 2000-04-20 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases

Publications (1)

Publication Number Publication Date
ATE516027T1 true ATE516027T1 (de) 2011-07-15

Family

ID=23138586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928256T ATE516027T1 (de) 1999-04-20 2000-04-20 Orazamid orotat zur vorbeugung von leberschäden

Country Status (7)

Country Link
US (1) US6184227B1 (de)
EP (1) EP1178796B1 (de)
JP (1) JP5073897B2 (de)
AT (1) ATE516027T1 (de)
AU (1) AU4651700A (de)
CA (1) CA2368165C (de)
WO (1) WO2000078311A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US20080000489A1 (en) * 2000-10-30 2008-01-03 Biohit Oyj Method and preparation for binding aldehydes in saliva
US20020110605A1 (en) * 2000-12-11 2002-08-15 Ryusuke Nakagiri Liver function protecting or improving agent
DE10124820A1 (de) 2001-05-21 2002-12-05 Heinrich Wieland Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
WO2006053010A2 (en) * 2004-11-09 2006-05-18 Hill's Pet Nutrition, Inc. Use of antioxidants for gene modulation
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
EP1830629A4 (de) * 2004-12-30 2008-08-27 Hills Pet Nutrition Inc Verfahren zur verbesserung der lebensqualität eines älteren tieres
EA200701434A1 (ru) * 2005-01-05 2008-10-30 Магд Ахмед Котб Абдалла Тауриновый синтез, производство и применение в качестве лекарственного средства
US7687473B2 (en) * 2005-01-07 2010-03-30 Health Research, Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
WO2008008380A1 (en) * 2006-07-12 2008-01-17 Regents Of The University Of Minnesota Combination therapy for addiction disorders
CN102846620B (zh) * 2012-10-22 2014-07-16 于可田 一种具有解酒醒酒作用的组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210865B (de) 1962-03-05 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung des 2, 6-dioxo-tetrahydropyrimidin-4-carbonsauren Salzes des 4-Amino-5-imidazolcarbonsaeureamids
FR2086266A1 (en) * 1970-04-23 1971-12-31 Selvi & C Lab Bioterapico Hepatic detoxicant amino-imidazolecarboxa-mido-ureidosuccinate
US3915982A (en) * 1973-01-31 1975-10-28 Kyowa Gas Chem Ind Co Ltd Imidazole derivatives and process for their preparation
HU190597B (en) * 1983-07-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing synrtgetic pharmaceutical compositions
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
EP0840608B1 (de) * 1995-07-21 2004-10-06 Savvipharm Inc. Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen

Also Published As

Publication number Publication date
US6184227B1 (en) 2001-02-06
CA2368165C (en) 2009-07-07
AU4651700A (en) 2001-01-09
JP2003526624A (ja) 2003-09-09
EP1178796A1 (de) 2002-02-13
WO2000078311A1 (en) 2000-12-28
JP5073897B2 (ja) 2012-11-14
EP1178796B1 (de) 2011-07-13
CA2368165A1 (en) 2000-12-28
EP1178796A4 (de) 2004-07-14

Similar Documents

Publication Publication Date Title
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
PT966465E (pt) Inibidores do enzima imfdh
BR9811099A (pt) Inibidores de urocinase
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
EA200100992A1 (ru) Ингибиторы фермента impdh
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200101166A1 (ru) Ингибиторы металлопротеаз
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
IL172773A0 (en) Formulations for the treatment of arhritis conditions
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE335739T1 (de) Cak inhibitoren und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties